The company plans to sell most of its drug-delivery business to an affiliate of Altaris Capital Partners for $650 million plus a 17% noncontrolling interest in the new company. 3M also will keep transdermal drug delivery components business.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,